In a groundbreaking development for pancreatic cancer treatment, a new drug called daraxonrasib has shown remarkable results in clinical trials. Patients with advanced pancreatic cancer, who previously faced limited options, are experiencing extended survival times thanks to this promising medication.
Clinical Trial Success
Dr. Zev Wainberg, co-director of UCLA Health’s GI Oncology Program, led a clinical trial involving 500 patients. The results were presented at the American Society of Clinical Oncology’s annual meeting in Chicago. The trial demonstrated that daraxonrasib doubled the average survival time for patients with advanced pancreatic cancer, from 6.7 months to 13.2 months.
Daraxonrasib targets a mutation in the KRAS gene, which is prevalent in over 90% of pancreatic cancers. This mutation causes uncontrolled cell growth, but the new drug acts as a ‘molecular glue,’ effectively inhibiting the mutated protein.
Hope for Broader Applications
The excitement surrounding daraxonrasib is not limited to pancreatic cancer. The drug’s mechanism of action suggests potential applications for other cancers, including lung, colorectal, ovarian, and bile duct cancers. Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, expressed optimism about the drug’s future uses.
The FDA has fast-tracked daraxonrasib for approval, and Revolution Medicines, the company behind the drug, is preparing to file for formal approval. Meanwhile, an expanded access program allows patients to receive the drug outside of clinical trials.
Patient Stories
Debby Orcutt, a 71-year-old patient from Spencer, Massachusetts, has experienced significant improvement since participating in the clinical trial. Her pancreatic tumor shrank by 80%, and she reports feeling great daily. Orcutt’s story is a testament to the potential life-changing impact of daraxonrasib.
While daraxonrasib is not a cure, it represents a significant step forward in cancer treatment. Patients and doctors alike are hopeful that this drug will pave the way for more effective therapies in the future.
Original reporting: NBC4 Los Angeles — read the source article.
